The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro–in vivo extrapolation of drug clearance and drug-drug interaction potential

References

• Alonen, A., Finel, M., Kostiainen, R. (2008). The human UDP-glucuronosyltransferase, UGT1A3, is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan. Biochem Pharmacol 76:763–772.
   PubMed Web of Science ®Google Scholar
• Barbier, O., Turgeon, D., Girard, C., Green, M. D., Tephly, T. R., Hum, D. W., et al. (2000). 3’-azido-3’-deoxythymidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Disp 28:497–502.
   PubMed Web of Science ®Google Scholar
• Barter, Z. E., Bayliss, M. K., Beaune, P. H., Boobis, A. R., Carlile, D. J., Edwards, R. J., et al. (2007). Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human liver microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 8:33–45.
   PubMed Web of Science ®Google Scholar
• Benoit-Biancamano, M-O., Connolly, J., Villeneuve, L., Caron, P., Guillemette, C. (2009). Deferiprone glucuronidation by human tissues and recombinant UDP-glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants. Drug Metab Disp 37:322–329.
   PubMed Web of Science ®Google Scholar
• Bernard, O., Guillemette, C. (2004). The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Disp 32:775–778.
   PubMed Web of Science ®Google Scholar
• Boase, S., Miners, J. O. (2002). In vitro–in vivo correlations for drugs cleared by glucuronidation: investigations with the model substrate, zidovudine. Br J Clin Pharmacol 54:493–503.
   PubMed Web of Science ®Google Scholar
• Bosma, P. J., Seppen, J., Goldhoorn, B., Bakker, C., Oude Elferink, R. P. J., Roy Cowdhury J., et al. (1994). Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem 269:17960–17964.
   PubMed Web of Science ®Google Scholar
• Bowalgaha, K., Elliot, D. J., Mackenzie, P. I., Knights, K. M., Swedmark, S., Miners, J. O. (2005). S-naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol 60:423–433.
   PubMed Web of Science ®Google Scholar
• Bowalgaha, K., Elliot, D. J., Mackenzie, P. I., Knights, K. M., Miners, J. O. (2007). The glucuronidation of δ4-3-keto C19 and C21 hydroxysteroids by human liver microsomal and recombinant UDP-glucuronosyltransferases (UGTs): 6α- and 21-hydroxyprogesterone are selective substrates for UGT2B7. Drug Metab Disp 35:363–370.
   PubMed Web of Science ®Google Scholar
• Boyd, M. A., Sraseuebkul, P., Ruxrunggtham, K., Mackenzie, P. I., Uchaipichat, V., Stek, M., et al. (2006). Relationship between hyperbilirubinemia and UDP-glucuronosyltransferase 1A1 polymorphism in HIV-infected Thai patients treated with indinavir. Pharmacogenet Genom 16:321–329.
   PubMed Web of Science ®Google Scholar
• Chen, G., Blevins-Primeau, A. S., Dellinger, R. W., Muscat, J. E., Lazarus, P. (2007). Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 codon 67 (Asp>Tyr) polymorphism. Cancer Res 67:9024–9029.
   PubMed Web of Science ®Google Scholar
• Court, M. H., Duan, S. X., Guillemette, C., Journault, K., Krishnaswamy, S., Hao, Q., et al. (2002). Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Disp 30:1257–1265.
   PubMed Web of Science ®Google Scholar
• Court, M. H., Krishnaswamy, S., Hao, Q., Duan, S. X., Patten, C. J., von Molte, L. L., et al. (2003). Evaluation of 3’-azido-3’-deoxythymidine, morphine and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Disp 31:1125–1133.
   PubMed Web of Science ®Google Scholar
• Court, M. H., Hao, Q., Krishnaswamy, S., Bekaii-Saab, T., Al-Rohaimi, A., von Molte, L. L., et al. (2004). UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are the major determinants of oxazepam glucuronidation by human liver. J Pharmacol Exp Ther 310:656–665.
   PubMed Web of Science ®Google Scholar
• Court, M. H. (2005). Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Meth Enzymol 400:104–116.
   PubMed Web of Science ®Google Scholar
• Court, M. H. (2009). Interindividual variability in hepatic drug glucuronidation: studies into the effects of genetic polymorphism, age, gender, and inducers using the human liver bank as a model system. Drug Metab Rev Issue 41:01.
   Google Scholar
• Cubitt, H. E., Houston, J. B., Galetin, A. (2009). Relative importance of intestinal and hepatic glucuronidation—impact on the prediction of drug clearance. Pharm Res 26:1073–1083.
   PubMed Web of Science ®Google Scholar
• Engtrakul, J. J., Foti, R. S., Strelevitz, T. J., Fisher, M. B. (2005). Altered AZT glucuronidation kinetics in human liver microsomes as an explanation for underprediction of in vivo clearance. Drug Metab Disp 33:1621–1627.
   PubMed Web of Science ®Google Scholar
• Fisher, M. B., Paine, M. F., Strelevitz, T. J., Wrighton, S. A. (2001). The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 33:273–297.
   PubMed Web of Science ®Google Scholar
• Foster, J. A., Hallifax, D., Houston, J. B. (2009). How robust is the prediction of in vivo metabolic clearance from established in vitro systems? Drug Metab Rev 41(Suppl 1):26.
   Google Scholar
• Gaganis, P., Miners, J. O., Knights, K. M. (2007). Glucuronidation of fenamates: kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7. Biochem Pharmacol 73:1683–1691.
   PubMed Web of Science ®Google Scholar
• Ghosal, A., Hapangama, N., Yuan, Y., Achanfuo-Yeboah, J., Iannucci, R., Chowdhury, S., et al. (2004). Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole. Drug Metab Disp 32:267–271.
   PubMed Web of Science ®Google Scholar
• Green, M. D., Bishop, W. P., Tephly, T. R. (1995). Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides. Drug Metab Disp 23:299–302.
   PubMed Web of Science ®Google Scholar
• Guillemette, C. (2003). Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenom J 3:136–158.
   PubMed Web of Science ®Google Scholar
• Hallifax, D., Houston, J. B. (2007). Saturable uptake of lipophilic amine drugs into isolated hepatocytes: mechanisms and consequences for quantitative clearance prediction. Drug Metab Disp 35:1325–1332.
   PubMed Web of Science ®Google Scholar
• Hallifax, D., Houston, J. B. (2009). Methodological uncertainty in quantitative prediction of human hepatic clearance from in vitro experimental systems. Curr Drug Metab 10:307–321.
   PubMed Web of Science ®Google Scholar
• Houston, J. B. (1994). Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469–1479.
   PubMed Web of Science ®Google Scholar
• Houston, J. B., Kenworthy, K. E. (2000). In vitro–in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Disp 28:246–254.
   PubMed Web of Science ®Google Scholar
• Hyland, R., Osborne, T., Payne, A., Kempshall, S., Logan, Y. R., Ezzedine, K., et al. (2009). In vitro and in vivo glucuronidation of midazolam in humans. Br J Clin Pharmacol 67:445–454.
   PubMed Web of Science ®Google Scholar
• Innocenti, F., Iyer, L., Ramirez, J., Green, M. D., Ratain, M. J. (2001). Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Disp 29:686–692.
   PubMed Web of Science ®Google Scholar
• Itaaho, K., Mackenzie, P. I., Ikushiro, S., Miners, J. O., Finel, M. (2008). The configuration of the 17-hydroxy group variably influences the glucuronidation of β-estradiol and epiestradiol by human UDP-glucuronosyltransferases. Drug Metab Disp 36:2307–2315.
   PubMed Web of Science ®Google Scholar
• Itaaho, K., Court, M. H., Uutela, P., Kostiainen, R., Radominska-Pandya, R., Finel, M. (2009). Dopamine is a low-affinity and high-specificity substrate for the human UDP-glucuronosyltransferase, 1A10. Drug Metab Disp 37:768–775.
   PubMed Web of Science ®Google Scholar
• Ito, K., Iwatsubo, T., Kanamitsu, S., Ueda, K., Sukuki, H., Sugiyama, Y. (1998). Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387–411.
   PubMed Web of Science ®Google Scholar
• Ito, K., Brown, H. S, Houston, J. B. (2004). Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473–486.
   PubMed Web of Science ®Google Scholar
• Ito, K., Houston, J. B. (2005). Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 22:103–112.
   PubMed Web of Science ®Google Scholar
• Jin, C-J., Miners, J. O., Burchell, B., Mackenzie, P. I. (1993a). The glucuronidation of hydroxylated metabolites of benzo[a]pyrene and 2-actylaminofluorene by cDNA expressed UDP-glucuronosyltransferases. Carcinogenesis 14:2637–2639.
   PubMed Web of Science ®Google Scholar
• Jin, C-J., Miners, J. O., Mackenzie, P. I. (1993b). cDNA cloning and expression of two new members of the human liver UDP-glucuronosyltransferase 2B subfamily. Biochem Biophys Res Commun 194:496–503.
   PubMed Web of Science ®Google Scholar
• Jin, C-J., Miners, J. O., Mackenzie, P. I. (1993c). Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate glucuronosyltransferase glucuronidating carboxylic acid containing drugs. J Pharmacol Exp Ther 264:475–479.
   PubMed Web of Science ®Google Scholar
• Jin, C-J., Mackenzie, P. I., Miners, J. O. (1997). The regio- and stereoselectivity of C19 and C21 hydroxysteroid glucuronidation by UGT2B7 and UGT2B11. Arch Biochem Biophys 341:207–211.
   PubMed Web of Science ®Google Scholar
• Jones, H. M., Houston, J. B. (2004). Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocytes and microsomal incubations. Drug Metab Disp 32:973–982.
   PubMed Web of Science ®Google Scholar
• Kaivosaari, S., Toivonen, P., Aitio, O., Sipila, J., Koskinen, M., Salonen, J. S., et al. (2008). Regio- and stereospecific N-glucuronidation of medetomidine: the differences between UDP-glucuronosyltransferase (UGT) 1A4 and UGT2B10 account for the complex kinetics of human liver microsomes. Drug Metab Disp 36:1529–1537.
   PubMed Web of Science ®Google Scholar
• Kaivosaari, S., Toivonen, P., Hesse, L. M., Koskinen, M., Court, M. H., Finel, M. (2007). Nicotine glucuronidation and the human UDP-glucuronosyltransferase UGT2B10. Mol Pharmacol 72:761–768.
   PubMed Web of Science ®Google Scholar
• Kaji, H., Kume, T. (2005). Regioselective glucuronidation of denopamine: marked species differences and identification of human UDP-glucuronosyltransferase isoform. Drug Metab Disp 33:403–412.
   PubMed Web of Science ®Google Scholar
• Kasai, N., Sakaki, T., Shinkyo, R., Ikushiro, S., Iyanagi, T., Ohta, M., et al. (2005). Metabolism of 26,26,26,27,27,27-F6-1α,23S,25-trihidroxyvitamin D3 by human UDP-glucuronosyltransferase 1A3. Drug Metab Disp 33:102–107.
   PubMed Web of Science ®Google Scholar
• Katoh, M., Matsui, T., Yokoi, T. (2007). Glucuronidation of antiallergic drug, tranilast: identification of human UDP-glucuronosyltransferase isoforms and effect of its phase I metabolite. Drug Metab Disp 35:583–589.
   PubMed Web of Science ®Google Scholar
• Kerdpin, O., Elliot, D. J., Mackenzie, P. I., Miners, J. O. (2006). Sulfinpyrazone C-glucuronidation is catalysed selectively by human UDP-glucuronosyltransferase 1A9. Drug Metab Disp 34:1950–1953.
   PubMed Web of Science ®Google Scholar
• Kiang, T. K. L., Ensom, M. H. H., Chang, T. K. H. (2005). UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106:97–132.
   PubMed Web of Science ®Google Scholar
• Kilford, P. J., Stringer, R., Sohal, B., Houston, J. B., Galetin, A. (2009). Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab Disp 37:82–89.
   PubMed Web of Science ®Google Scholar
• Klieber, S., Hugla, S., Ngo, R., Arabeyre-Fabre, C., Meuniere, V., Sadoun, F., et al. (2008). Contribution of the N-glucuronidation pathway to overall in vitro metabolic clearance of midazolam in humans. Drug Metab Disp 36:851–862.
   PubMed Web of Science ®Google Scholar
• Knights, K. M., Miners, J. O. (2009). Renal UDP-glucuronosyltransferases and the glucuronidation of xenobiotics and endogenous mediators. Drug Metab Rev Issue 41:01.
   Web of Science ®Google Scholar
• Knights, K. M., Winner, L. K., Elliot, D. J., Bowalgaha, K., Miners, J. O. (2009). Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs. Br J Clin Pharmacol Br J Clin Pharmacol 68:402–412.
   PubMed Web of Science ®Google Scholar
• Krishnaswamy, S., Duan, S. X., von Moltke, L. L., Greenblatt, D. J., Court, M. H. (2003). Validation of serotonin (5-hydroxytryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6. Drug Metab Disp 31:133–139.
   PubMed Web of Science ®Google Scholar
• Kubota, T., Lewis, B. C., Elliot, D. J., Mackenzie, P. I., Miners, J. O. (2007). Critical roles of residues 36 and 40 in the phenol and tertiary amine aglycone substrate selectivities of UDP-glucuronosyltransferases 1A3 and 1A4. Mol Pharmacol 72:1054–1062.
   PubMed Web of Science ®Google Scholar
• Lepine, J., Bernard, O., Plante, M., Tetu, B., Pelletier, G., Labrie, F., et al. (2004). Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium. J Clin Endocrinol Metab 89:5222–5232.
   PubMed Web of Science ®Google Scholar
• Lewis, B. C., Mackenzie, P. I., Elliot, D. J., Burchell, B., Bhasker, C. R., Miners, J. O. (2007). Amino terminal domains of human UDP-glucuronosyltransferase (UGT) 2B7 and 2B15 associated with substrate selectivity and autoactivation. Biochem Pharmacol 73:1463–1473.
   PubMed Web of Science ®Google Scholar
• Linnet, K. (2002). Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. Hum Psychopharmacol 17:233–238.
   PubMed Web of Science ®Google Scholar
• Mackenzie, P. I., Bock, K. W., Burchell, B., Guillemette, C., Ikushiro, S., Iyanagi, T., et al. (2005). Nomenclature update for the mammalian UDP-glucuronosyltransferase (UGT) gene family. Pharmacogenet Genom 15:677–685.
   PubMed Web of Science ®Google Scholar
• Mano, Y., Usui, T., Kamimura, H. (2007a). Predominant contribution of UDP-glucuronosyltransferase 2B7 in the glucuronidation of racemic flurbiprofen in the human liver. Drug Metab Disp 35:1182–1187.
   PubMed Web of Science ®Google Scholar
• Mano, Y., Usui, T., Kamimura, H. (2007b). The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab Disp 35:2040–2044.
   PubMed Web of Science ®Google Scholar
• McLure, J. A., Miners, J. O., Birkett, D. J. (2000). Nonspecific binding of drugs to human liver microsomes. Br J Clin Pharmacol 49:453–461.
   PubMed Web of Science ®Google Scholar
• Miners, J. O., Mackenzie, P. I. (1991). Drug glucuronidation in humans. Pharmacol Ther 51:347–369.
   PubMed Web of Science ®Google Scholar
• Miners, J. O., Veronese, M. E., Birkett, D. J. (1994). In vitro approaches for the prediction of human drug metabolism. Annu Rep Med Chem 29:307–316.
   Web of Science ®Google Scholar
• Miners, J. O., Valente, L., Lillywhite, K. J., Mackenzie, P. I., Burchell, B., Baguley, B. C., et al. (1997). Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acteic acid, a new anticancer drug. Cancer Res 57:284–289.
   PubMed Web of Science ®Google Scholar
• Miners, J. O., McKinnon, R. A., Mackenzie, P. I. (2002). Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology 181–182:453–456.
   Google Scholar
• Miners, J. O., Smith, P. A., Sorich, M. J., McKinnon, R. A., Mackenzie, P. I. (2004). Predicting human drug glucuronidation parameters: application of in vitro and in silico modelling approaches. Annu Rev Pharmacol Toxicol 44:1–25.
   PubMed Web of Science ®Google Scholar
• Miners, J. O., Knights, K. M., Houston, J. B., Mackenzie, P. I. (2006). In vitro–in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 71:1531–1539.
   PubMed Web of Science ®Google Scholar
• Mistry, M., Houston, J. B. (1987). Glucuronidation in vitro and in vivo—comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine. Drug Metab Disp 15:710–717.
   PubMed Web of Science ®Google Scholar
• Nakajima, M., Tanaka, E., Kobayashi, T., Ohashi, N., Kume, T., Yokoi, T. (2002). Imipramine N-glucuronidation in human liver microsomes: biphasic kinetics and characterization of UDP-glucuronosyltransferase isoforms. Drug Metab Disp 30:636–642.
   PubMed Web of Science ®Google Scholar
• Nishiyama, T., Kobori, T., Arai, K., Ogura, K., Ohnuma, T., Ishii, K., et al. (2006). Identification of human UDP-glucuronosyltransferase isoforms(s) responsible for the C-glucuronidation of phenylbutazone. Arch Biochem Biophys 454:72–79.
   PubMed Web of Science ®Google Scholar
• Obach, R. S. (1997). Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Disp 25:1359–1369.
   PubMed Web of Science ®Google Scholar
• Ohno, S., Nakajin, S. (2009). Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Disp 37:32–40.
   PubMed Web of Science ®Google Scholar
• Ohno, S, Kawana, K., Nakajin, S. (2008). Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine 6-glucuronidation and its kinetic properties. Drug Metab Disp 36:688–694.
   PubMed Web of Science ®Google Scholar
• Oleson, L., Court, M. H. (2008). Effect of the β-glucuronidase inhibitor, saccharolactone, on glucuronidation by human liver microsomes and recombinant UDP-glucuronosyltransferases. J Pharm Pharmacol 60:1175–1182.
   PubMed Web of Science ®Google Scholar
• Picard, N., Ratanasavanh, D., Premaud, A., Le Meur, Y., Marquet, P. (2005). Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Disp 33:130–146.
   Google Scholar
• Polasek, T. M., Miners, J. O. (2007). In vitro approaches to investigate mechanism-based inactivation of cytochromes P450. Exp Opin Drug Metab Toxicol 3:321–329.
   PubMed Web of Science ®Google Scholar
• Procter, N. J., Tucker, G. T., Rostami-Hodjegan, A. (2004). Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 34:151–178.
   PubMed Web of Science ®Google Scholar
• Radominska-Pandya, A., Czernik, P. J., Little, J. A., Battaglia, E, Mackenzie, P. I. (1999). Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 31:817–899.
   PubMed Web of Science ®Google Scholar
• Riley, R. J., McGinnity, D. F., Austin, R. P. (2005). A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Disp 33:1304–1311.
   PubMed Web of Science ®Google Scholar
• Rowland, A., Elliot, D. J., Williams, J. A., Mackenzie, P. I., Dickinson, R. G., Miners, J. O. (2006). In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Disp 35:1055–1062.
   Google Scholar
• Rowland, A., Gaganis, P., Elliot, D. J., Mackenzie, P. I., Knights, K. M., Miners, J. O. (2007). Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro–in vivo extrapolation. J Pharmacol Exp Ther 321:137–147.
   PubMed Web of Science ®Google Scholar
• Rowland, A., Knights, K. M., Mackenzie, P. I., Miners, J. O. (2008a). The albumin effect and drug glucuronidation: bovine serum albumin and fatty-acid–free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Disp 36:1056–1062.
   PubMed Web of Science ®Google Scholar
• Rowland, A., Elliot, D. J., Knights, K. M., Mackenzie, P. I., Miners, J. O. (2008b). The albumin effect and in vitro–in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9. Drug Metab Disp 36:870–877.
   PubMed Web of Science ®Google Scholar
• Rowland, A., Knights, K. M., Mackenzie, P. I., Miners, J. O. (2009). Characterization of the binding of drugs to human intestinal fatty acid binding protein (IFABP): potential role of IFABP as an alternative to albumin for in vitro–in vivo extrapolation of drug kinetic parameters. Drug Metab Disp 37:1395–1403.
   PubMed Web of Science ®Google Scholar
• Soars, M. G., Burchell, B., Riley, R. J. (2002). In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 301:382–390.
   PubMed Web of Science ®Google Scholar
• Soars, M. G., Ring, B. J., Wrighton, S. A. (2003). The effect of incubation conditions on the enzyme kinetics of UDP-glucuronosyltransferases. Drug Metab Disp 31:762–767.
   PubMed Web of Science ®Google Scholar
• Soars M. G., Petullo, D. M., Eckstein, J. A., Kasper, S. C., Wrighton, S. A. (2004). An assessment of UDP-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab Disp 32:140–148.
   PubMed Web of Science ®Google Scholar
• Sorich, M. J., McKinnon, R. A., Miners, J. O., Smith, P. A. (2006). The importance of local chemical structure for chemical metabolism by human uridine 5’-diphosphate glucuronosyltransferase. J Chem Inf Model 46:2692–2697.
   PubMed Web of Science ®Google Scholar
• Stone, A. N., Mackenzie, P. I., Galetin, A., Houston, J. B., Miners, J. O. (2003). Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Disp 31:1086–1089.
   PubMed Web of Science ®Google Scholar
• Tsoutsikos, P., Miners, J. O., Stapleton, A., Thomas, A., Sallustio, B. C., Knights, K. M. (2004). Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. Biochem Pharmacol 67:191–199.
   PubMed Web of Science ®Google Scholar
• Uchaipichat, V., Mackenzie, P. I., Guo, X-H., Gardner-Stephen, D., Galetin, A., Houston, J. B., et al. (2004). Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Disp 34:413–423.
   Google Scholar
• Uchaipichat, V., Mackenzie, P. I., Elliot, D. J., Miners, J. O. (2006a). Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) “probes” for human UDP-glucuronosyltransferases. Drug Metab Disp 34:449–456.
   PubMed Web of Science ®Google Scholar
• Uchaipichat, V., Winner, L. K., Mackenzie, P. I., Elliot, D. J., Williams, J. A., Miners, J. O. (2006b). Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol 61:427–439.
   PubMed Web of Science ®Google Scholar
• Uchaipichat, V., Galetin, A., Houston, J. B., Mackenzie, P. I., Williams, J. A., Miners, J. O. (2008). Kinetic modelling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by UDP-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate and effector binding sites. Mol Pharmacol 74:1152–1162.
   PubMed Web of Science ®Google Scholar
• Udomuksorn, W., Elliot, D. J., Lewis, B. C., Mackenzie, P. I., Yoovathaworn, K., Miners, J. O. (2007). Influence of mutations associated with the Gilbert’s and Crigler-Najjar type II syndromes on the glucuronidation of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenet Genom 17:1017–11029.
   PubMed Web of Science ®Google Scholar
• Watanabe, Y., Nakajima, M., Ohashi, N., Kume, T., Yokoi, T. (2003). Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1. Drug Metab Disp 31:89–95.
   Google Scholar
• Wen, Z., Tallman, M. N., Ali, S. Y., Smith, P. C. (2007a). UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Disp 35:371–380.
   PubMed Web of Science ®Google Scholar
• Wen, Z., Martin, D. E., Bullock, P., Lee, K-H., Smith, P. C. (2007b). Glucuronidation of an anti-HIV drug candidate, beviramat: identification of human UDP-glucuronosyltransferases and species differences. Drug Metab Disp 35:440–448.
   PubMed Web of Science ®Google Scholar
• Williams, J. A., Ring, B. J., Cantrell, V. E., Campanale, K., Jones, D. R., Hall, S. D., et al. (2002). Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) catalyzed estradiol 3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Disp 30:1266–1273.
   PubMed Web of Science ®Google Scholar
• Zhu, B., Bush, D., Doss, G. A., Vincent, S., Franklin, R. B., Xu., S. (2008). Characterization of 1’-hydroxymidazolam glucuronidation in human liver microsomes. Drug Metab Disp 36:331–338.
   PubMed Web of Science ®Google Scholar